Apremilast - 3SBio

Drug Profile

Apremilast - 3SBio

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator 3SBio
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Isoindoles; Phthalimides; Small molecules; Sulfones
  • Mechanism of Action Interleukin 23 inhibitors; Tumour necrosis factor alpha inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Psoriatic arthritis

Most Recent Events

  • 27 Sep 2016 Chemical structure information added
  • 22 Sep 2016 Phase-I clinical trials in Psoriatic arthritis in China before September 2016 (3SBio pipeline, September 2016)
  • 01 Mar 2016 Preclinical trials in Psoriatic arthritis in China before March 2016 (3SBio website, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top